Redmile Group, LLC Bluebird Bio, Inc. Transaction History

Redmile Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $14.9 Million - $23.5 Million	-252,100 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $1.46 Million - $1.93 Million	-16,400 Reduced 6.11%	252,100 $36.8 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $139,496 - $178,626	1,400 Added 0.52%	268,500 $42.1 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $772,340 - $1.1 Million	7,300 Added 2.81%	267,100 $0
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $21.1 Million - $34 Million	259,800	259,800 $46.3 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.